Catalyst steps up to provide LEMS patients expanded Firdapse access
This article was originally published in Scrip
Executive Summary
After recognizing some patients with a rare autoimmune neuromuscular disease, known as Lambert-Eaton myasthenic syndrome (LEMS), were unable to access treatment for their disease, Florida drug maker Catalyst Pharmaceutical Partners stepped up and initiated the process to establish an expanded access program (EAP) for its experimental potassium channel inhibitor Firdapse (amifampridine phosphate).
You may also be interested in...
Phase III Data Support Catalyst's NDA Resubmission For Firdapse
Catalyst executives note that the company has completed everything the FDA requested to support resubmission of Firdapse for its first two rare disease indications – a second Phase III study in LEMS and abuse liability studies.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.